CytoMed Therapeutics (GDTC) Competitors $2.10 +0.09 (+4.48%) Closing price 04:00 PM EasternExtended Trading$2.15 +0.05 (+2.38%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GDTC vs. RAPT, CTNM, SGMT, MGNX, COYA, HLVX, OPTN, CHRS, IMUX, and VXRTShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include RAPT Therapeutics (RAPT), Contineum Therapeutics (CTNM), Sagimet Biosciences (SGMT), MacroGenics (MGNX), Coya Therapeutics (COYA), HilleVax (HLVX), OptiNose (OPTN), Coherus BioSciences (CHRS), Immunic (IMUX), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. CytoMed Therapeutics vs. RAPT Therapeutics Contineum Therapeutics Sagimet Biosciences MacroGenics Coya Therapeutics HilleVax OptiNose Coherus BioSciences Immunic Vaxart CytoMed Therapeutics (NASDAQ:GDTC) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Which has preferable valuation and earnings, GDTC or RAPT? CytoMed Therapeutics has higher earnings, but lower revenue than RAPT Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytoMed Therapeutics$69.50K345.51-$3.13MN/AN/ARAPT Therapeutics$1.53M76.61-$116.80M-$2.40-0.37 Does the media favor GDTC or RAPT? In the previous week, RAPT Therapeutics had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for RAPT Therapeutics and 1 mentions for CytoMed Therapeutics. RAPT Therapeutics' average media sentiment score of 1.50 beat CytoMed Therapeutics' score of -0.08 indicating that RAPT Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytoMed Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral RAPT Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals & insiders have more ownership in GDTC or RAPT? 0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 2.4% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor GDTC or RAPT? RAPT Therapeutics received 87 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 63.19% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformCytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo VotesRAPT TherapeuticsOutperform Votes9163.19% Underperform Votes5336.81% Is GDTC or RAPT more profitable? CytoMed Therapeutics' return on equity of 0.00% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytoMed TherapeuticsN/A N/A N/A RAPT Therapeutics N/A -89.10%-76.13% Do analysts recommend GDTC or RAPT? CytoMed Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 127.79%. RAPT Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 351.47%. Given RAPT Therapeutics' higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00RAPT Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more risk and volatility, GDTC or RAPT? CytoMed Therapeutics has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.04, indicating that its stock price is 104% less volatile than the S&P 500. SummaryRAPT Therapeutics beats CytoMed Therapeutics on 9 of the 15 factors compared between the two stocks. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.01M$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E RatioN/A8.9726.6219.77Price / Sales345.51253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book2.816.486.814.53Net Income-$3.13M$143.98M$3.23B$248.18M7 Day Performance-6.60%3.37%4.05%1.06%1 Month Performance-3.73%7.83%11.64%14.68%1 Year Performance7.60%-2.24%17.11%6.87% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics1.596 of 5 stars$2.10+4.5%$5.00+138.1%-1.0%$22.97M$69,501.000.00N/AGap UpRAPTRAPT Therapeutics4.406 of 5 stars$0.75-14.9%$4.00+434.8%-75.9%$98.73M$1.53M-0.2780Positive NewsGap DownCTNMContineum Therapeutics2.2039 of 5 stars$3.81-0.5%$23.75+523.4%-75.6%$98.57M$50M-0.7831Earnings ReportAnalyst ForecastSGMTSagimet Biosciences1.5851 of 5 stars$3.18-3.9%$22.40+604.4%-27.6%$97.55M$2M-2.228Positive NewsGap UpMGNXMacroGenics3.5702 of 5 stars$1.54-3.1%$7.43+382.4%-63.1%$97.16M$148.34M-0.97430News CoverageAnalyst ForecastGap DownCOYACoya Therapeutics2.0971 of 5 stars$5.76-6.2%$17.00+195.1%-34.1%$96.34M$3.55M-8.866Trending NewsAnalyst RevisionGap UpHLVXHilleVax2.5015 of 5 stars$1.92+1.6%$3.00+56.3%-86.1%$96.27MN/A-0.6220News CoveragePositive NewsOPTNOptiNose2.9772 of 5 stars$9.45+0.3%$9.00-4.8%-46.7%$95.70M$78.23M-2.25190News CoverageAnalyst ForecastAnalyst RevisionCHRSCoherus BioSciences3.7165 of 5 stars$0.83-19.1%$4.68+467.6%-60.8%$95.65M$266.96M-10.31330News CoverageAnalyst DowngradeIMUXImmunic2.5844 of 5 stars$0.99+0.3%$13.20+1,233.6%-24.5%$94.84MN/A-0.8070Earnings ReportGap DownVXRTVaxart2.3856 of 5 stars$0.42+2.6%$3.00+622.0%-43.3%$94.82M$28.70M-1.01120News CoverageHigh Trading Volume Related Companies and Tools Related Companies RAPT Competitors CTNM Competitors SGMT Competitors MGNX Competitors COYA Competitors HLVX Competitors OPTN Competitors CHRS Competitors IMUX Competitors VXRT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GDTC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
